Core Scientific, Inc.

Based on the provided data, here is a comprehensive analysis of CORZ.

Technical Analysis CORZ exhibits extreme volatility, with a massive beta of nearly 7 indicating dramatic swings compared to the market. Recent performance is mixed: a strong 18.6% gain over three months is tempered by a nearly 10% drop in the last month, suggesting recent profit-taking. Currently priced in the upper-middle of its 52-week range, the sharp pullback may offer a slightly better entry point after its significant rally.

Fundamental Analysis The fundamentals are concerning. While revenue shows modest growth, the company is deeply unprofitable with a net income margin of -181% and deteriorating operational efficiency. Its financial health is unconventional, with a negative debt-to-equity ratio and poor asset utilization, indicating it is not effectively using its capital to generate sales or profits.

Valuation & Risk Valuation is impractical due to negative earnings and cash flow, making standard metrics meaningless. The primary risk is extreme volatility; the stock's price is highly unstable and susceptible to severe downturns, as shown by its 42% maximum drawdown. While not heavily shorted, the combination of high volatility and weak fundamentals creates a speculative and high-risk profile.

Final Recommendation: AVOID

CORZ is a highly speculative stock unsuitable for most investors. The extreme price volatility, coupled with deeply negative profitability and an inefficient operational structure, presents significant risks of capital loss. While the recent pullback might tempt traders, the absence of a clear fundamental recovery path or reasonable valuation makes an investment difficult to justify. Investors should seek opportunities with more stable financial footing.

RockFlow Model Forecast: Three Scenarios for 2026

Based on the provided analysis, the 12-month outlook for CORZ is highly speculative and carries significant risk. The primary positive catalyst is the stock's inherent extreme volatility, which could lead to sharp, short-lived rallies driven by retail sentiment or speculative news, offering potential for short-term traders. However, the major risks are overwhelming and stem from its deeply unprofitable operations, negative cash flow, and poor capital efficiency, indicating no clear fundamental recovery path. In the absence of a viable business turnaround, the stock faces a high risk of substantial capital loss. Given the lack of analyst coverage and meaningful valuation metrics, a target price range cannot be established, but the overall risk-reward profile is skewed negatively.

Wall Street Consensus

Most Wall Street analysts are optimistic about Core Scientific, Inc.'s 12-month outlook, with consensus target around $16.97, indicating expected upside potential.

Overall, CORZ has investment potential but also faces challenges. Here are key factors to weigh before investing.

CORZ has demonstrated extreme volatility with substantial gains over three months but significant short-term pressure. The stock's exceptionally high beta of 6.885 indicates it is dramatically more volatile than the broader market.

Short-term performance shows conflicting signals, with an 18.6% gain over three months significantly outperforming the market by nearly 13 percentage points. However, the stock has retreated 9.83% over the past month, suggesting recent selling pressure despite the strong medium-term outperformance.

Currently trading at $17.98, CORZ sits approximately 66% above its 52-week low but 24% below its high, positioning it in the upper-middle range of its yearly spectrum. Given the recent pullback from nearer peak levels and the extreme volatility, the stock may be moving toward less overbought territory after its substantial rally.

Revenue & Profitability CORZ shows concerning profitability despite modest revenue growth from $78.6M to $81.1M quarter-over-quarter. The company maintains extremely thin gross margins of 4.7% while operating at substantial losses, with operating income ratios worsening from -33% to -81% and net income margins deeply negative at -181%. These metrics indicate severe operational inefficiencies relative to revenue generation.

Financial Health The company's balance sheet shows moderate liquidity with current and quick ratios of 1.58, though the cash ratio of 0.68 suggests limited immediate cash coverage. The negative debt-to-equity ratio of -0.94 and debt ratio of 0.46 reflect an unusual capital structure, while the cash flow to debt ratio of 0.12 indicates limited cash generation relative to obligations.

Operational Efficiency CORZ demonstrates poor asset utilization with an extremely low asset turnover of 0.035, indicating inefficient use of assets to generate revenue. Despite negative returns on assets (-6.4%) and capital employed (-4.0%), the return on equity stands at 13.0%, reflecting significant financial leverage rather than operational strength. The negative cash conversion cycle of -247 days suggests the company is effectively financing operations through extended payment terms.

Valuation Level CORZ's negative trailing and forward PE ratios indicate the company is currently unprofitable on a GAAP earnings basis, making traditional PE-based valuation assessment impractical. The negative price-to-book and EV/EBITDA ratios further confirm that valuation cannot be meaningfully evaluated using these metrics, as the company is generating losses rather than earnings or positive cash flow.

Peer Comparison Without industry average data, a comparative valuation analysis cannot be performed. The absence of peer benchmarks limits the ability to determine whether CORZ’s negative valuation multiples are typical for its sector or indicative of broader challenges. Further context from industry comparables would be necessary to draw meaningful conclusions about relative valuation.

Volatility risk is exceptionally high, as evidenced by an extraordinary beta of 6.885, indicating the stock's price is nearly seven times more volatile than the broader market. This extreme sensitivity is further confirmed by a substantial 1-year maximum drawdown of -42.74%, highlighting the potential for significant capital depreciation during market downturns.

Other risks appear moderate, with the absence of significant short interest suggesting the market does not hold a broadly bearish view on the stock. However, the combination of extreme volatility and potentially lower trading liquidity could still lead to sharp, unpredictable price movements.